Implicit Bioscience
Seattle, US · Delaware corporation
Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment. The company's work is validated through peer-reviewed research in leading cardiology journals.
Founders & leadership
GR
Garry RedlichCEO & MD, Co-founder
PP
Prof. Peter AndrewsChairman, Co-founder
JE
James Edward RottsolkExecutive
MK
Marion KosterinChief Financial Officer and Company Secretary
BW
Brian William ZiegelaarExecutive
Board
DD
Daniel David SyrdalBoard director
LL
Lee Lawrence HuntsmanBoard director
NL
Norman LemayBoard director
RN
Richard Neil MarsdenBoard director
Reported raises · per SEC filings
Form D private placements$818.6K disclosed across 5 rounds · 2015–2020
▶$65.6KraisedSep 2020 · 2 investors · BiotechnologyRule 506(b)
▶$65.6KraisedSep 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter Ronald AndrewsDirector
- Ian Hector FrazerDirector
- Marion KosterExecutive Officer
- Peter Camac Huntley FryDirector
- Garry Llewellyn RedlichExecutive Officer, Director
- Amount sold
- $65.6K
- Proceeds to insiders
- $156K
- First sale
- Aug 2020
- Incorporated
- Other, Australia
- Federal exemptions
- 06b
▶$367.2KraisedSep 2019 · 4 investors · BiotechnologyRule 506(b)
▶$367.2KraisedSep 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian William ZiegelaarExecutive Officer
- Marion KosterExecutive Officer
- Peter Camac Huntley FryDirector
- Ian Hector FrazerDirector
- Peter Ronald AndrewsDirector
- Garry Llewellyn RedlichExecutive Officer, Director
- Amount sold
- $367.2K
- Proceeds to insiders
- $230K
- First sale
- Sep 2019
- Incorporated
- Other, Australia
- Federal exemptions
- 06b
▶$125KraisedSep 2017 · 3 investors · BiotechnologyRule 506(b)
▶$125KraisedSep 2017 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Brian William ZiegelaarExecutive Officer
- Ian Hector FrazerDirector
- Richard Neil MarsdenDirector
- Marion KosterExecutive Officer
- Garry Llewellyn RedlichExecutive Officer, Director
- Peter Ronald AndrewsDirector
- Offering amount
- $1.6M
- Amount sold
- $125K
- Minimum investment
- $19.3K
- Proceeds to insiders
- $120K
- First sale
- Sep 2017
- Incorporated
- Other, Australia
- Federal exemptions
- 06b
▶$210.1KraisedSep 2016 · 3 investors · BiotechnologyRule 506(b)
▶$210.1KraisedSep 2016 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel David SyrdalDirector
- Brian William ZiegelaarExecutive Officer
- Marion KosterExecutive Officer
- Garry Llewellyn RedlichExecutive Officer, Director
- Peter Ronald AndrewsDirector
- Richard Neil MarsdenDirector
- Offering amount
- $750K
- Amount sold
- $210.1K
- Proceeds to insiders
- $120K
- First sale
- Sep 2016
- Incorporated
- Other, Australia
- Federal exemptions
- 06b
▶$50.8KraisedNov 2015 · 4 investors · BiotechnologyRule 506(b)
▶$50.8KraisedNov 2015 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James Edward RottsolkExecutive Officer, Director
- Marion KosterExecutive Officer
- Daniel David SyrdalDirector
- Lee Lawrence HuntsmanDirector
- Norman LemayDirector
- Garry Llewellyn RedlichExecutive Officer, Director
- Offering amount
- $7M
- Amount sold
- $50.8K
- Minimum investment
- $1
- Finders' fees
- $14K
- Proceeds to insiders
- $108K
- Placement agents
- RB Milestone Group LLC
- First sale
- Sep 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Implicit Bioscience do?
- Implicit BioScience develops therapeutic approaches targeting cardioimmunology, specifically using CD14 blockade to modulate immune responses in acute heart attack (STEMI) treatment. The company's work is validated through peer-reviewed research in leading cardiology journals.
- Who founded Implicit Bioscience?
- Implicit Bioscience was founded by Garry Redlich, Prof. Peter Andrews.
- How much funding has Implicit Bioscience raised?
- Implicit Bioscience has disclosed $818.6K raised across 5 rounds.
- Where is Implicit Bioscience headquartered?
- Implicit Bioscience is headquartered in Seattle, US.